An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assesse...
| Autores: | ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Tipo de documento: | Artículo |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Lenguaje: | Inglés |
| OAI Identifier: | oai:ddd.uab.cat:186277 |
| Acceso en línea: | https://ddd.uab.cat/record/186277 https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | Activities of daily living Levodopa-carbidopa intestinal gel Parkinson's disease Percutaneous endoscopic gastrojejunostomy Quality of life |
| _version_ | 1878742513469095937 |
|---|---|
| author | Krüger, Rejko|||0000-0003-4258-6241 |
| author2 | Lingor, Paul Doskas, Triantafyllos Henselmans, Johanna M. L. Danielsen, Erik H. Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338 Stefani, Alessandro Sensken, Sven-Christian Parra, Juan Carlos Onuk, Koray Yegin, Ashley Antonini, Angelo|||0000-0003-1040-2807 |
| author2_role | author author author author author author author author author author author |
| author_browse | Antonini, Angelo|||0000-0003-1040-2807 Danielsen, Erik H. Doskas, Triantafyllos Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338 Henselmans, Johanna M. L. Krüger, Rejko|||0000-0003-4258-6241 Lingor, Paul Onuk, Koray Parra, Juan Carlos Sensken, Sven-Christian Stefani, Alessandro Yegin, Ashley |
| author_facet | Krüger, Rejko|||0000-0003-4258-6241 Lingor, Paul Doskas, Triantafyllos Henselmans, Johanna M. L. Danielsen, Erik H. Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338 Stefani, Alessandro Sensken, Sven-Christian Parra, Juan Carlos Onuk, Koray Yegin, Ashley Antonini, Angelo|||0000-0003-1040-2807 |
| author_role | author |
| collection | Dipòsit Digital de Documents de la UAB |
| description | Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients. This prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily. Patients received LCIG via PEG-J for 16 h continuously. Effectiveness was assessed using Unified PD Rating Scale parts II and III, the Non-Motor Symptom Scale, and the PD Questionnaire-8. The mean (SD) treatment duration was 275 (157) days. Patients experienced significant improvement from baseline in activities of daily living at final visit (p < 0.05) as well as at months 3 and 6 (p < 0.0001). Patients also experienced significant improvements from baseline in quality of life and non-motor symptoms at all time points (p < 0.001 for all). Specifically, patients manifested significant improvements in mean change from baseline at every study visit in five of nine non-motor symptom score domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous. One-third of patients (32.8%) experienced an adverse event; 21.9% experienced a serious adverse event; 11.1% discontinued because of an adverse event. This study demonstrated significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of non-motor symptoms after treatment with LCIG. AbbVie Inc. The online version of this article (doi:10.1007/s12325-017-0571-2) contains supplementary material, which is available to authorized users. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_f74a053a92425a5aa2b1a2a0b770e2e0 |
| institution | Universitat Autònoma de Barcelona |
| instname_str | Universitat Autònoma de Barcelona |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:ddd.uab.cat:186277 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| reponame_str | Dipòsit Digital de Documents de la UAB |
| spelling | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients Krüger, Rejko|||0000-0003-4258-6241 Lingor, Paul Doskas, Triantafyllos Henselmans, Johanna M. L. Danielsen, Erik H. Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338 Stefani, Alessandro Sensken, Sven-Christian Parra, Juan Carlos Onuk, Koray Yegin, Ashley Antonini, Angelo|||0000-0003-1040-2807 Activities of daily living Levodopa-carbidopa intestinal gel Parkinson's disease Percutaneous endoscopic gastrojejunostomy Quality of life Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients. This prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily. Patients received LCIG via PEG-J for 16 h continuously. Effectiveness was assessed using Unified PD Rating Scale parts II and III, the Non-Motor Symptom Scale, and the PD Questionnaire-8. The mean (SD) treatment duration was 275 (157) days. Patients experienced significant improvement from baseline in activities of daily living at final visit (p < 0.05) as well as at months 3 and 6 (p < 0.0001). Patients also experienced significant improvements from baseline in quality of life and non-motor symptoms at all time points (p < 0.001 for all). Specifically, patients manifested significant improvements in mean change from baseline at every study visit in five of nine non-motor symptom score domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous. One-third of patients (32.8%) experienced an adverse event; 21.9% experienced a serious adverse event; 11.1% discontinued because of an adverse event. This study demonstrated significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of non-motor symptoms after treatment with LCIG. AbbVie Inc. The online version of this article (doi:10.1007/s12325-017-0571-2) contains supplementary material, which is available to authorized users. https://ddd.uab.cat/record/186277 https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2 |
| spellingShingle | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients Krüger, Rejko|||0000-0003-4258-6241 Activities of daily living Levodopa-carbidopa intestinal gel Parkinson's disease Percutaneous endoscopic gastrojejunostomy Quality of life |
| title | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| title_full | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| title_fullStr | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| title_full_unstemmed | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| title_short | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| title_sort | An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients |
| topic | Activities of daily living Levodopa-carbidopa intestinal gel Parkinson's disease Percutaneous endoscopic gastrojejunostomy Quality of life |
| topic_facet | Activities of daily living Levodopa-carbidopa intestinal gel Parkinson's disease Percutaneous endoscopic gastrojejunostomy Quality of life |
| url | https://ddd.uab.cat/record/186277 https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2 |